Terex Corp
Change company Symbol lookup
Select an option...
TEX Terex Corp
JEPI JPMorgan Equity Premium Income ETF
SPYD SPDR® Portfolio S&P 500 High Dividend ETF
AAPL Apple Inc
VYM Vanguard High Dividend Yield Index Fund ETF Shares
DGRO iShares Core Dividend Growth ETF
DIVO Amplify CWP Enhanced Dividend Income ETF
SCHD Schwab U.S. Dividend Equity ETF™
VYMI Vanguard International High Dividend Yield Index Fund ETF Shares
SRE Sempra Energy
Go

Industrials : Machinery | Small Cap Blend
Company profile

Terex Corporation designs, builds, and supports products used in construction, maintenance, manufacturing, energy, minerals, and materials management applications. The Company segments include Aerial Work Platforms (AWP) and Materials Processing (MP). AWP segment designs, manufactures, services and markets aerial work platform equipment, utility equipment and telehandlers. Its products include portable material lifts, portable aerial work platforms, self-propelled articulating and telescopic booms, scissor lifts, and replacement parts. MP segment designs, manufactures, services and markets materials processing and specialty equipment, including crushers, washing systems, screens, apron feeders, material handlers, pick and carry cranes, rough terrain cranes, tower cranes, wood processing, concrete mixer trucks and concrete pavers, conveyors, environmental and recycling solutions, and their related components and replacement parts.

Closing Price
$52.49
Day's Change
0.79 (1.53%)
Bid
--
Ask
--
B/A Size
--
Day's High
52.50
Day's Low
51.07
Volume
(Above Average)
Volume:
765,720

10-day average volume:
642,173
765,720

GE Healthcare and ulrich medical announce an Agreement to Offer a Branded Multi-dose Contrast Media Injector in the U.S.

7:00 am ET November 28, 2022 (BusinessWire) Print

GE Healthcare has today announced an agreement with ulrich medical for a GE Healthcare branded contrast media injector in the U.S. The CT motion multi-dose syringeless injector, which delivers iodinated contrast media for Computed Tomography (CT) imaging procedures, reduces procedure setup time and increases patient throughput by eliminating time consuming preparation steps, while helping to optimize patient dosing and reduce wasted contrast media.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221125005300/en/

Recent research, led by Dushyant Sahani MD, Professor and Chair of Radiology at the University of Washington and presented at the 2022 Radiological Society of North America (RSNA) Congress, demonstrates that when compared to a typical dual-syringe based injector using single or multi-dose vials, the CT motion may enable six additional patient CT exams each day in a busy Emergency Department, with up to three minutes saved per patient. The research, which analyzed over 6,000 patients who received Contrast Enhanced CT or CT Angiography, also shows CT Motion reduces cost from consumables and saves an average 30 mL of contrast per procedure.

The U.S. contrast media injector market is estimated to grow at 4.3 percent annuallyi between 2022-2030, attributed to its developed healthcare infrastructure and the prevalence of chronic diseases.

Today, the majority of contrast enhanced CT imaging involves radiology technicians filling a syringe with contrast media prior the injection procedure. With the syringeless CT motion, the required dose is drawn and injected directly from the injector's contrast media container, saving time, facilitating the optimal volume of contrast media will be used, reducing wasted leftover contrast and generating less disposable waste. CT motion also provides injection reports accessible via RIS/PACS for dose management systems and records of prior injections to further optimize dose and improve patient safety.

Marco Campione, Americas General Manager at GE Healthcare Pharmaceutical Diagnostics said: "Radiology departments are focused on managing increasing demand and on conserving contrast media. The CT motion supports efficient operational practices - saving time, saving contrast, saving on consumables, improving workflows and facilitates better patient throughput. We expect demand for iodinated contrast media to double in the next decade, so we are investing, both in production capacity expansion and also in technologies like this that conserve volumes and reduce leftover contrast media."

Klaus Kiesel, CEO ulrich medical, said: "We are delighted to be working even more closely with our long-standing partner GE Healthcare, who have already been distributing our injector CT motion in the US market. With GE Healthcare's nationwide brand recognition and great distribution power, we are sure to significantly expand our market share on injectors in the world's largest medical technology market."

As part of its broader commitment to address growing demand for iodinated contrast media, GE Healthcare recently opened a new 30 million USD additional manufacturing line at its facility in Cork, Ireland, announced an 80 million USD investment to increase capacity at its Active Pharmaceutical Ingredients site in Lindesnes, Norway, and signed an agreement with the Chile based mining company, SQM, to secure an increasing supply of the key raw material, iodine. These milestones are contributing to GE Healthcare's aim to produce 30 million more patient doses of iodinated contrast media annually by 2025.

GE Healthcare's Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. All stages of its contrast media manufacturing, from development of API to finished product, are managed entirely by GE Healthcare, adhering to current Good Manufacturing Practices (cGMP). With over 4000 employees globally and seven manufacturing sites, the business also develops and supplies radiopharmaceuticals used to support diagnosis, monitoring and treatment selection across Neurology, Cardiology and Oncology clinical pathways.

Dr Sahani will present an abstract from the GE Healthcare funded study "Improving CT workflow and in a busy subspeciality emergency room using a novel power injector technology" on November 30th at 8:00 am - 9:00 am CT, during Session W1-SSNPM03: Noninterpretive Skills/Quality Improvement/Practice Management (Optimizing Radiology Care Delivery)

ENDS

About CT motion Developed by ulrich medical, based in Ulm, Germany, the design of the CT motion draws on 30 years of medical imaging experience and is already used globally. For the U.S. market, the CT motion injector is manufactured in Germany and shipped, distributed and serviced by GE Healthcare. The injector is indicated by the U.S. Food and Drug Administration (FDA) for intravenous use in CT of head and body with GE Healthcare's iodinated contrast media.

About ulrich medical: ulrich GmbH & Co. KG, ulrich medical for short, develops, produces and distributes spinal systems and contrast medium injectors. The family-owned company, founded in 1912, celebrates its 110th anniversary in 2022 and employs a total of around 500 people at its headquarters in Ulm and its two subsidiaries in France and the USA. While the products are used worldwide, the medical technology company focuses on "Made in Germany" quality, making it one of the few in the industry that consistently develops and manufactures its products in Germany. ulrich medical successfully underwent an MDR audit in January 2020 - as one of the first medical technology manufacturers in Germany. In addition, the F.A.Z. Institute named ulrich medical one of the "Innovation Leaders of Germany 2020".

About GE Healthcare: GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website www.gehealthcare.com for more information.

i www.grandviewresearch.com/industry-analysis/contrast-media-injectors-market

View source version on businesswire.com: https://www.businesswire.com/news/home/20221125005300/en/

SOURCE: GE Healthcare

Media Contact: 
Debbie Leven
Debbie.Leven@ge.com 
+44 7785 456999
comtex tracking

COMTEX_419868270/1006/2022-11-28T07:00:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.